Throughout the last three months, 9 analysts have evaluated Molina Healthcare (NYSE:MOH), offering a diverse set of opinions from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 0 | 3 | 5 | 1 | 0 |
| Last 30D | 0 | 0 | 0 | 1 | 0 |
| 1M Ago | 0 | 1 | 2 | 0 | 0 |
| 2M Ago | 0 | 1 | 2 | 0 | 0 |
| 3M Ago | 0 | 1 | 1 | 0 | 0 |
The 12-month price targets, analyzed by analysts, offer insights with an average target of $198.11, a high estimate of $231.00, and a low estimate of $144.00. A decline of 7.53% from the prior average price target is evident in the current average.
Investigating Analyst Ratings: An Elaborate Study
The analysis of recent analyst actions sheds light on the perception of Molina Healthcare by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Andrew Mok | Barclays | Lowers | Underweight | $144.00 | $185.00 |
| Erin Wright | Morgan Stanley | Raises | Equal-Weight | $204.00 | $163.00 |
| Scott Fidel | Goldman Sachs | Announces | Neutral | $207.00 | - |
| Stephen Baxter | Wells Fargo | Raises | Overweight | $231.00 | $198.00 |
| Lance Wilkes | Bernstein | Lowers | Outperform | $220.00 | $284.00 |
| Andrew Mok | Barclays | Lowers | Equal-Weight | $185.00 | $186.00 |
| Sarah James | Cantor Fitzgerald | Maintains | Neutral | $210.00 | $210.00 |
| Stephen Baxter | Wells Fargo | Lowers | Overweight | $198.00 | $216.00 |
| John Stansel | JP Morgan | Lowers | Neutral | $184.00 | $272.00 |
Key Insights:
- Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Molina Healthcare. This offers insight into analysts' perspectives on the current state of the company.
- Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Molina Healthcare compared to the broader market.
- Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.
For valuable insights into Molina Healthcare's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
Stay up to date on Molina Healthcare analyst ratings.
Delving into Molina Healthcare's Background
Molina Healthcare Inc offers healthcare plans focused on Medicaid-related solutions for low-income families and individuals. Its health plans are operated by a network of subsidiaries, each of which is licensed as a health maintenance organization (HMO). It has four segments: Medicaid, Medicare, Marketplace and Others. The Medicaid, Medicare, and Marketplace segments represent the government-funded or sponsored programs under which it offers managed healthcare services. The Other segment, which is insignificant to its consolidated results of operations, includes long-term services and supports consultative services in Wisconsin. It generates majority revenue from Medicaid segment.
Molina Healthcare's Economic Impact: An Analysis
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Positive Revenue Trend: Examining Molina Healthcare's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 0.44% as of 30 September, 2025, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Molina Healthcare's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 0.69%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Molina Healthcare's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 1.8%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Molina Healthcare's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 0.5%, the company may face hurdles in achieving optimal financial returns.
Debt Management: With a high debt-to-equity ratio of 0.92, Molina Healthcare faces challenges in effectively managing its debt levels, indicating potential financial strain.
The Basics of Analyst Ratings
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
